Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,208.12 +80.43 (+7.13%)
Official Closing Price Updated: 7:00 PM EDT, Jun 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
News headline image
Eli Lilly Q4 Preview: Wall St Sees Revenue Beat On Weight-Loss Heft But R&amp;D Costs Could Drag Profits ↗
Eli Lilly (LLY) Q4 Preview: Analysts predict a $17.9B revenue beat, but rising R&D costs could challenge the $6.96 EPS target. 
Via Benzinga
News headline image
Eli Lilly (LLY) Reports Q4: Everything You Need To Know Ahead Of Earnings
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Wednesday before market hours. Here’s what to expect. 
Via StockStory
News headline image
Google Stock Hits Record High, Leads Select Group Of 14 Stocks Onto Best Stock lists ↗
Search and AI data center king Google closed at 343.69 Monday. It was up 1.7% for the day and popped to a record close. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs
As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those... 
Via MarketMinute
Topics Economy Government Intellectual Property
Eli Lilly & Co (NYSE:LLY) Emerges as a Top GARP Investment Candidate ↗
Via Chartmill
News headline image
The Biological Singularity: How AlphaFold 3 Is Rewriting the Blueprint of Drug Discovery
As of early 2026, the promise of “digital-first” drug discovery has shifted from a speculative horizon to a tangible industrial reality. Since its groundbreaking release in May 2024, AlphaFold 3... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Is Novo Nordisk Stock a Bargain Right Now? ↗
Novo Nordisk just introduced a GLP-1 pill, but the company makes more than just weight-loss drugs. 
Via The Motley Fool
News headline image
VenHub Appoints Former Amazon Executive, Ian Rasmussen, to Spearhead Nationwide Smart Store Expansion with Focus on Strategic Partnerships and Enterprise Integrations
VenHub Global, Inc. (NASDAQ:VHUB) (“VenHub” or the “Company”), a leader in fully autonomous Smart Store technology, today announced the appointment of Ian Rasmussen as 
Via PressReach
News headline image
3 Headwinds Facing Pfizer in 2026 ↗
Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Where Will AbbVie Be in 5 Years? ↗
A prediction for AbbVie in 2031: The drugmaker will be bigger and kinglier. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Commodity Volatility, Earnings and Other Key Things to Watch
Markets enter February following a volatile final trading day of January that saw investors grappling with hotter-than-expected inflation data alongside news of a new Federal Reserve chair nominee. 
Via Barchart.com
Topics Economy
News headline image
Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch? ↗
This could finally be the start of the drugmaker's comeback. 
Via The Motley Fool
News headline image
Eli Lilly CEO Says Medicare Coverage Of Obesity Drugs Could Be Game-Changer For Its Weight-Loss Pill ↗
Eli Lilly CEO Dave Ricks said upcoming Medicare coverage of obesity drugs could be a game-changer for the launch of its experimental weight-loss pill orforglipron, potentially expanding access to... 
Via Benzinga
News headline image
Eli Lilly CEO Sees Medicare Coverage Support Upcoming Obesity Pill Launch: Report ↗
CEO Dave Ricks said in an interview with CNBC that many patients are currently paying in cash for the oral obesity drug from rival Novo Nordisk. 
Via Stocktwits
Topics Government
News headline image
Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally? ↗
Novo Nordisk's weight loss pill could give the company's numbers a big boost this year. 
Via The Motley Fool
News headline image
Stock Yards Bank Buys $25 Million of Stock Yards Bancorp Stock ↗
Stock Yards Bancorp delivers commercial banking and wealth management services across key Midwest metropolitan markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Novo Nordisk Outspends Eli Lilly On Wegovy, Ozempic Ads After Supply Crunch Eases ↗
Novo Nordisk sharply increased U.S. advertising for Wegovy and Ozempic in 2025, outspending Eli Lilly as competition for obesity drugs intensified. 
Via Benzinga
News headline image
FDA Decision on Eli Lilly's Weight Loss Pill Delayed to Q2. Is This Bad News for the Stock? ↗
The target action date for orforglipron is now April 10. 
Via The Motley Fool
News headline image
Should You Buy Eli Lilly Before Feb. 4? ↗
Is there another beat-and-raise in the pharmaceutical giant's near future? 
Via The Motley Fool
News headline image
Should You Buy Guardant Health Before Feb. 19? ↗
This genomics stock appears to be at an inflection point. 
Via The Motley Fool
Topics Earnings
News headline image
Eli Lilly Teams Up With Two Biotechs To Target Autoimmune Disease, Hearing Loss In Deals Worth $3 Billion ↗
Eli Lilly signs major deals with Repertoire Immune and Seamless Therapeutics, committing billions to autoimmune disease treatments and gene therapies targeting hearing loss. 
Via Benzinga
News headline image
How Roche Hopes To Go Toe-To-Toe With Eli Lilly, Novo Nordisk In Obesity ↗
Roche hopes to rival Eli Lilly and Novo Nordisk in the weight-loss space. 
Via Investor's Business Daily
News headline image
Prediction: Artificial Intelligence (AI) Will Reshape This Industry by 2030. This Stock Could Lead. ↗
This pharmaceutical giant is increasingly looking unstoppable. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Can This Beaten-Down AI Stock Bounce Back in 2026? ↗
It might take a while for this AI company to prove its worth, if it ever does so. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy. ↗
Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future. 
Via The Motley Fool
News headline image
FDA Codifies AI’s Role in Drug Production: New 2026 Guidelines Set Global Standard for Pharma Safety and Efficiency
In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial... 
Via TokenRing AI
Topics Artificial Intelligence Economy
News headline image
The Biological Singularity: How Nobel-Winning AlphaFold 3 is Rewriting the Blueprint of Life
In the annals of scientific history, few moments represent a clearer "before and after" than the arrival of AlphaFold 3. Developed by Google DeepMind and its dedicated drug-discovery arm, Isomorphic... 
Via TokenRing AI
Topics Artificial Intelligence Economy
News headline image
Lilly Bolsters Immunology Arsenal with $1.2 Billion Acquisition of Ventyx Biosciences
In a strategic move to solidify its dominance in the burgeoning field of oral anti-inflammatories, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, a definitive agreement to acquire... 
Via MarketMinute
News headline image
Eli Lilly Strikes $1.1 Billion Deal With Seamless Therapeutics To Develop Gene Therapies For Hearing Loss ↗
Under the terms of the deal between Seamless Therapeutics and Eli Lilly, Seamless will design and program site-specific enzymes to correct mutations in certain genes related to hearing loss. 
Via Stocktwits
Topics Economy Government
News headline image
Top Picks 2026: Eli Lilly & Co. ↗
LLY is surging as its weight-loss duopoly remains a 2026 
Via Talk Markets
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.